Drugs / SCT650C
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05894707 | Jun → Nov 2023 | autoimmune disease | Sinocelltech Ltd. | Unknown | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT07244510 Comparator | Dec 2025 → Mar 2027 expected | hidradenitis suppurativa | Sinocelltech Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06197009 Comparator | Jul 2024 → Jul 2026 overdue | spondyloarthropathy | Sinocelltech Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCT650C | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06197009 ↗ |
| Modality | Monoclonal antibody | “novel humanized monoclonal antibody” NCT05894707 ↗ |
| Route | Subcutaneous | “Administered SC” NCT06197009 ↗ |
| Target | IL17A | “against human IL-17A” NCT05894707 ↗ |